Navigation Links
Bristol Myers Squibb to Speak at Pharmica Consulting’s Resource and Portfolio Management Conference
Date:1/29/2013

Princeton, NJ (PRWEB) January 29, 2013

(PRWEB) January 29, 2013 – Pharmica Consulting is widely considered to be the life sciences expert in operational excellence. As part of its continued service to the life sciences industry, Pharmica will be hosting its Second Resource and Portfolio Management Conference on April 11, 2013 in Princeton, NJ. The one day conference will highlight demos, real world case studies, and help the industry better understand best practices in resource management, reporting tools, portfolio management, and how to implement the right system and processes for the size and needs of your organization. Greg Bayer, Group Director, R&D Scheduling & Resource Management at Bristol Myers Squibb, has been added to the agenda as a speaker.

“Greg Bayer has been a thought leader in the resource and portfolio management space for over ten years,” said Eric Lake, Partner with Pharmica Consulting. “We are excited to have Greg as a speaker and look forward to the discussion with the audience.”

“Portfolio, resource and budget decisions during the annual R&D budgeting process are never easy,” said Matt Kiernan, Partner with Pharmica Consulting. “It’s one of the primary drivers for why we implement these capabilities. Yet, many companies still struggle with how to support and make decisions during the annual portfolio review process. Greg’s experience and guidance to industry members will be greatly valued at the conference.”

“Resourcing and portfolio management has been a critical part of any pharma operations for decades,” adds Jim Wetzel, Principal Consultant at Pharmica. “However, the manner in which the work force has changed with remote workers, the boom of outsourcing and partnerships and the use of contractors have put an even greater emphasis on knowing what your resources are doing.”

We are excited about the presentations from not only from BMS but also, Biogen, J&J, Allergan and others," said Matt Kiernan, Partner with Pharmica Consulting.

Those interested in learning more about Pharmica Consulting’s service offerings can visit http://www.PharmicaConsulting.com. To request additional information, please contact Matt Kiernan at 610-945-4364 or Jim Wetzel at 610-996-3113.

About Pharmica Consulting- Pharmica Consulting, one of the life sciences industry’s leading consulting firms, provides a variety of offerings designed to help pharmaceutical and biotech clients achieve true Operational Excellence. Consultants at Pharmica invest the time needed to truly understand a client’s specific challenges—and tailor solutions to help them create a more profitable business environment. Pharmica Consulting knows how to build effective strategies—and deliver against those strategies as promised.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10345238.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Biogen to Speak at Pharmica Consulting’s Resource and Portfolio Management Conference
2. Pictures Speak Louder Than Words on Cigarette Labeling
3. LifeWings CEO to Speak at Virginia Patient Safety Summit in January
4. Paramount Lists Will Be Speaking At The National Postal Forum In San Francisco
5. Marketing Xocolate International Corporation (MXI Corp) Launches “The Whole Story” World Tour To Highlight Xocai Healthy Chocolate Product, Full-Line Up of Guest Speakers
6. Ruben Rives, H2Only Renewable Cleaning, to Speak at MiaGreen Expo
7. Lifetime of Speaking a 2nd Language May Boost Aging Brain
8. Author, Speaker, Healer, Nina Brown Recognized by 2012 USA Best Book Awards
9. New York Times Columnist, Thomas Friedman To Visit As Part Of This Year's Sacramento Speakers Series January 8th
10. College-Bound Girls May Feel Pressure to Speak Properly
11. GMS Talent L P announces Stephen J. Blakesley Speaks to The Organizational Development Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: